# KPD Consolidation After ASCT in NDMM Patients

> **NCT06879379** · PHASE2,PHASE3 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 202 (estimated)

## Conditions studied

- Multiple Myeloma, Newly Diagnosed

## Interventions

- **DRUG:** KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation

## Key facts

- **NCT ID:** NCT06879379
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06879379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06879379, "KPD Consolidation After ASCT in NDMM Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06879379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*